SIVEXTRO (tedizolid), antibiotic of the oxazolidinone class

• SIVEXTRO has Marketing Authorisation in the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults.

• It does not provide any therapeutic benefit by comparison with linezolid, since:

-       its in-vitro activity profile, efficacy and safety are comparable with that of linezolid;

-       and considering the insufficient documentation of clinical efficacy and safety in severe skin infections and/or skin infections caused by multidrug-resistant bacteria.

• It may be offered in infections regardless of severity for which a staphylococcal aetiology is proven or suspected (suppurative infections) and where resistance to methicillin is proven or strongly suspected.